Aldevron will host the inaugural Breakthrough Symposium, November 6-7, 2018, in Fargo, North Dakota.
Gene and cell therapy and gene editing have seen tremendous growth, and 2017 saw product approvals that will begin the transformation of medicine and how we treat disease. This two-day event will bring together biotech industry scientists and product developers, government researchers, medical professionals and members of the academic community to share the latest breakthroughs and explore the incredible potential in the field.
Speakers will present a wide array of topics, including clinical results, novel approaches to gene delivery and modification, and the latest manufacturing advances. The symposium will spur discussion and inspire attendees to continue pursuing biotechnology breakthroughs that improve the lives of people around the world.
Tom Whitehead, co-founder of the Emily Whitehead Foundation, is a keynote speaker and will share his family’s inspiring firsthand knowledge of the impact of biotechnology through his daughter Emily’s cancer treatment. Emily is a three-time cancer survivor and was the first child in the world to receive the CAR-T cell therapy treatment that is now an approved product, Kymriah, sold by Novartis.
The theme of this year’s event – Taking Biotech as Far as It Can Go – recognizes the collaboration necessary to achieve the scientific breakthroughs vital to industry advancement. It also embraces the event's unique location – Fargo, North Dakota, which is home to Aldevron’s headquarters and new production facility. Event attendees will have the opportunity to tour the facility as part of the event.
Submissions for the symposium’s poster session are currently being accepted. Abstract guidelines are available at www.breakthroughsymposium.com/posters. Potential speakers and/or sponsors are encouraged to contact James Brown at email@example.com, or 701.499.7330.
For more information about the Breakthrough Symposium, including agenda details, submission guidelines and registration information, visit www.breakthroughsymposium.com.
Aldevron serves the biotechnology industry with custom production of nucleic acids, proteins, and antibodies. Thousands of clients use Aldevron-produced plasmids, RNA and gene editing enzymes for projects ranging from discovery research to clinical trials to commercial applications. These products are critical raw materials and key components in commercially available drugs and medical devices. Aldevron specializes in GMP manufacturing and is known for inventing the GMP-SourceTM quality system. Company headquarters are in Fargo, North Dakota, with additional facilities in Madison, Wisconsin, and Freiburg, Germany.